The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Eli Lilly (LLY) is taking legal action against makers of off-brand versions of its blockbuster diabetes and weight-loss drugs ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

Eli Lilly is broadening its direct-to-consumer approach by partnering with a digital health company, Noom, which is focused on weight management. The collaboration connects Noom users with Eli Lilly’s ...

Genetics or hormonal changes can pose challenges for losing weight, as you may know firsthand. Like many others struggling to ...

Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy will have the option to buy now and pay later under a partnership announced Tuesday by ...

Tirzepatide has been shown to help people lose more weight compared to semaglutide at the dosage regimens currently available ...

Eli Lilly has benefitted from the windfall from tirzepatide – the active ingredient in its weight loss injection Zepbound and diabetes shot Mounjaro – which targets GLP-1 but also activates ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...